What is Sunshine Biopharma Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sunshine Biopharma's cash to debt ratio for the quarter that ended in Mar. 2024 was 28.49.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Sunshine Biopharma could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.
The historical rank and industry rank for Sunshine Biopharma's Cash-to-Debt or its related term are showing as below:
SBFM'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.31 Max: No Debt
Current: 28.49
During the past 13 years, Sunshine Biopharma's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was 0.31.
Sunshine Biopharma Cash-to-Debt Historical Data
The historical data trend for Sunshine Biopharma's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Sunshine Biopharma Cash-to-Debt Chart
|
Sunshine Biopharma Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
0.06 |
0.52 |
1.08 |
28.53 |
24.76 |
|
Sunshine Biopharma Quarterly Data
|
|
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
26.29 |
27.44 |
27.96 |
24.76 |
28.49 |
Competitive Comparison of Sunshine Biopharma's Cash-to-Debt
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma's Cash-to-Debt Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's Cash-to-Debt falls into.
Sunshine Biopharma Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Sunshine Biopharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
Sunshine Biopharma's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma (Sunshine Biopharma) Business Description
Traded in Other Exchanges
N/A
Address
6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).
Executives
| Camille Sebaaly |
director, officer: CFO and Secretary |
14464 GOUIN W., #B, MONTREAL A8 H9H 1B1 |
| Malek Chamoun |
10 percent owner |
1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2 |
| David Natan |
director |
11190 BISCAYNE BLVD, MIAMI FL 33181 |
| Andrew Mark Keller |
director |
10 ISLAND DRIVE, NORWALK CT 06855 |
| Andrew I Telsey |
director |
6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111 |
| James Daniel Kish |
director |
6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111 |
| Rabi Kiderchah |
director |
924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3 |
| Advanomics Corp |
10 percent owner |
579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4 |
| Steve N. Slilaty |
director, 10 percent owner, officer: CEO and President |
579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4 |
| Abderrazzak Merzouki |
director, officer: Chief Operating Officer |
731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1 |
| Turi Michele Di |
director, officer: Chief Operating Officer |
3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3 |
Sunshine Biopharma (Sunshine Biopharma) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SBFM has been successfully added to your